FDA Approves Cefepime-Zidebactam Injection - Top-Institutions - MDSpire

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.

  • By

  • Kathryn Wighton

  • June 3, 2026

  • 2 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Rutgers Robert Wood Johnson Medical School
    Rutgers Robert Wood Johnson Medical School

    New Brunswick, NJ

    Key Differentiators

    • Infectious Disease

  • #2

    Second Xiangya Hospital of Central South University
    Second Xiangya Hospital of Central South University

    Changsha, Hunan

    Key Differentiators

    • Infectious Disease

  • #3

    University of Maryland
    University of Maryland

    Baltimore, MD

    Key Differentiators

    • Infectious Disease

Original Source(s)

FDA Approves Cefepime-Zidebactam Injection

  • by Kathryn Wighton

  • June 3, 2026

Related Content

May Clearing Nasal Viruses Improve Allergic Rhinitis?

A phase 2 randomized trial suggests reducing nasal commensal viruses with ribavirin spray may improve allergic rhinitis symptoms while supporting a proposed disease mechanism.

Why Is Vaginal Estrogen Still Underused?

A large Epic Cosmos analysis linked vaginal estrogen prescribing with lower rates of sepsis, hospital admission, and death following recurrent urinary tract infection, but researchers cautioned that prescribing may also mark broader differences in care.

Hospital AI Fails to Flag Drug Diversion

"I've never myself seen these technologies be called out in that specific way"